SLS SELLAS LIFE SCIENCES GROUP INC US FDA Inspections 8-K Filing 2025 - Trial Update SELLAS Life Sciences announced the interim analysis results of its Phase 3 REGAL trial for galinpepimut-S in treating acute myeloid leukemia, highlighting the ongoing development and future milestones while acknowledging risks and uncertainties.Get access to all SEC 8-K filings of the SELLAS LIFE SCIENCES GROUP INC